Impaired High‐Density Lipoprotein Function in Patients With Heart Failure

Autor: Congzhuo Jia, Stefan D. Anker, Dirk J. van Veldhuisen, Johanna E. Emmens, Chim C. Lang, Gerasimos Filippatos, John G.F. Cleland, Kenneth Dickstein, Uwe J. F. Tietge, Leong L. Ng, Rudolf A. de Boer, Marco Metra, Adriaan A. Voors
Přispěvatelé: Cardiovascular Centre (CVC), Center for Liver, Digestive and Metabolic Diseases (CLDM)
Rok vydání: 2021
Předmět:
Male
Proteomics
medicine.medical_specialty
HDL
Proteome
Lipoproteins
030204 cardiovascular system & hematology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
High-density lipoprotein
Internal medicine
medicine
cholesterol efflux
functionality
high‐density lipoprotein
outcome
proteome
Aged
Biomarkers
Case-Control Studies
Europe
Female
Follow-Up Studies
Heart Failure
Humans
Lipoproteins
HDL
Survival Rate
In patient
030212 general & internal medicine
Cholesterol efflux
Functionality
Original Research
Outcome
Lipids and Cholesterol
biology
Cholesterol
business.industry
Hazard ratio
nutritional and metabolic diseases
medicine.disease
Endocrinology
chemistry
Heart failure
biology.protein
lipids (amino acids
peptides
and proteins)
Apolipoprotein A1
Efflux
Cardiology and Cardiovascular Medicine
business
Lipoprotein
Zdroj: e019123
Journal of the American Heart Association (JAHA)
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Journal of the American Heart Association, 10(9):e019123. Wiley
ISSN: 2047-9980
DOI: 10.1161/jaha.120.019123
Popis: Background We recently showed that, in patients with heart failure, lower high‐density lipoprotein (HDL) cholesterol concentration was a strong predictor of death or hospitalization for heart failure. In a follow‐up study, we suggested that this association could be partly explained by HDL proteome composition. However, whether the emerging concept of HDL function contributes to the prognosis of patients with heart failure has not been addressed. Methods and Results We measured 3 key protective HDL function metrics, namely, cholesterol efflux, antioxidative capacity, and anti‐inflammatory capacity, at baseline and after 9 months in 446 randomly selected patients with heart failure from BIOSTAT‐CHF (A Systems Biology Study to Tailored Treatment in Chronic Heart Failure). Additionally, the relationship between HDL functionality and HDL proteome composition was determined in 86 patients with heart failure. From baseline to 9 months, HDL cholesterol concentrations were unchanged, but HDL cholesterol efflux and anti‐inflammatory capacity declined (both P P P =0.001). Other functionality measures were not associated with outcome. Several HDL proteins correlated with HDL functionality, mainly with cholesterol efflux. Apolipoprotein A1 emerged as the main protein associated with all 3 HDL functionality measures. Conclusions Better HDL cholesterol efflux at baseline was associated with lower mortality during follow‐up, independent of HDL cholesterol. HDL cholesterol efflux and anti‐inflammatory capacity declined during follow‐up in patients with heart failure. Measures of HDL function may provide clinical information in addition to HDL cholesterol concentration in patients with heart failure.
Databáze: OpenAIRE
Externí odkaz: